APA (7th ed.) Citation

Hsu, Y., Chen, C., Chang, I., Chang, C., Wu, C., Lee, T., . . . Lin, J. (2021). Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): A multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. The Lancet infectious diseases, 21(6), 823-833. https://doi.org/10.1016/S1473-3099(20)30692-7

Chicago Style (17th ed.) Citation

Hsu, Yao-Chun, et al. "Once-daily Tenofovir Disoproxil Fumarate in Treatment-naive Taiwanese Patients with Chronic Hepatitis B and Minimally Raised Alanine Aminotransferase (TORCH-B): A Multicentre, Double-blind, Placebo-controlled, Parallel-group, Randomised Trial." The Lancet Infectious Diseases 21, no. 6 (2021): 823-833. https://doi.org/10.1016/S1473-3099(20)30692-7.

MLA (9th ed.) Citation

Hsu, Yao-Chun, et al. "Once-daily Tenofovir Disoproxil Fumarate in Treatment-naive Taiwanese Patients with Chronic Hepatitis B and Minimally Raised Alanine Aminotransferase (TORCH-B): A Multicentre, Double-blind, Placebo-controlled, Parallel-group, Randomised Trial." The Lancet Infectious Diseases, vol. 21, no. 6, 2021, pp. 823-833, https://doi.org/10.1016/S1473-3099(20)30692-7.